Kyle Doherty

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear cell renal cell carcinoma.

The combination of benmelstobart with anlotinib led to efficacy improvements in patients with advanced renal cell carcinoma vs sunitinib.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Adding retifanlimab to carboplatin and paclitaxel improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.

Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.

Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.

New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.

Zanubrutinib plus venetoclax achieved a 100% overall response rate in patients with treatment-naive CLL/SLL harboring 17p deletions and/or TP53 mutations.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.

According to findings from the phase 3 ESOPEC trial, perioperative chemotherapy given with FLOT improved overall survival in resectable esophageal cancer.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Among patients with Ph-positive chronic phase chronic myeloid leukemia, asciminib demonstrated positive results, including a better major molecular response rate at 48 weeks vs investigator-selected TKIs.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.

A study found that UGN-102, used alone or combined with TURBT, resulted in comparable duration of response and disease-free survival rates in both patients newly diagnosed with and those with recurrent low-grade/intermediate non-muscle invasive bladder cancer.

Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.

Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

An increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.

Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.

An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.

As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival and complete response rate.

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.

Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

ARX517 showed early efficacy in patients with metastatic castration-resistant prostate cancer in the phase 1/2 APEX-01 study.